Search results
Results from the WOW.Com Content Network
The human protein is also frequently referred to as HER2 (human epidermal growth factor receptor 2) or CD340 (cluster of differentiation 340). [5] [6] [7]
The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]
The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 , Her3 , and Her4 . The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are ...
She was part of the investigative team who discovered that the HER2/neu molecule is a tumor-specific marker, or antigen. [ 4 ] [ 5 ] She is the founding editor in chief of JAMA Oncology .
Shepard and Hudziak discovered that too much HER2 made tumor cells grow better. Then made a key discovery about how HER2 can cause resistance to immune cell killing of tumor cells. Overexpression of HER2 makes cells resistant to killing by macrophages, which are the first line of defense against cancer.
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
The supermodel explained that a doctor called her after she had a lumpectomy and told her it was HER2 positive estrogen receptive intraductal carcinoma, which is a type of breast cancer, per the ...
Of these, HER2/neu (also known as Erb-B2) was the first to be developed. The molecule is highly expressed in a variety of cancer cell types, most notably breast cancer. As such, antibodies against HER2/neu have been FDA approved for clinical treatment of cancer under the drug name Herceptin.